The mouse CD8α+ Clec9a+ DCs (or stem-DCs) produced in this study demonstrated antitumor effects characterized not only by a reduced volume of ascites and number of tumor implants but also high levels of immunostimulatory cells and cytokines and low levels of immunosuppressive cytokines. The gene discussed is CLEC9A; the disease is neoplasm.